Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02713867 |
| Title | A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) |
| Acronym | CheckMate 384 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Bristol-Myers Squibb |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS |